Accelerating Science: How to cure the incurable with cell and gene therapy

SureSelect Cancer CGP Assay ​ by Agilent Technologies

Manufacturer Agilent Technologies  |  Available Worldwide

SureSelect Cancer CGP assay offers comprehensive genomic profiling for solid tumors. This pan-cancer NGS panel enables detection of somatic variants, including single nucleotide variants (SNVs), copy number variants (CNVs), insertions/deletions (indels), translocations (TLs), gene fusions, and the immuno-oncology biomarkers TMB (tumor mutational burden) and MSI (microsatellite instability).


SureSelect Cancer CGP Assay ​ by Agilent Technologies product image
SureSelect Cancer CGP Assay ​
Request Pricing

Receive your quote directly from the manufacturer.



0 Scientists have reviewed this product


Write the First Review

No Reviews

SureSelect Cancer CGP assay offers comprehensive genomic profiling for solid tumors. This pan-cancer NGS panel enables detection of somatic variants, including single nucleotide variants (SNVs), copy number variants (CNVs), insertions/deletions (indels), translocations (TLs), gene fusions, and the immuno-oncology biomarkers TMB (tumor mutational burden) and MSI (microsatellite instability).

Powered by SureSelect XT HS2 library preparation and target enrichment chemistry, the assay features fast hybridization, low sample input, enzymatic fragmentation, and a one-day workflow to generate NGS sequencing-ready libraries. Automation options reduce hands-on time to maximize lab efficiency.

  • Globally curated gene content (679 genes for DNA, 80 genes for RNA) sourced from cancer databases and leading clinical cancer researchers
  • Improved lab efficiency with automation, including the benchtop Agilent Magnis NGS Prep system that requires minimal expertise and only 15 minutes of hands-on time for walkaway convenience and the Agilent Bravo NGS workstation, a liquid handling platform for scaling up to 96 samples per run
  • Enzymatic fragmentation option eliminates the need for physical shearing equipment
  • Start with input as low as 10 ng DNA (recommended 50 ng) to enable profiling of more samples
  • Fast hybridization (90 minutes) for library preparation in a single day
  • Detection of de novo gene fusions (80 genes) requiring only one gene partner
  • Developed for multiple sample types including FFPE
  • Modular workflow allows the option to assay DNA and RNA separately or together in the same sequencing run
  • Integrated data analysis with Agilent Alissa Clinical Informatics Platform. Also compatible with customer in-house informatics and 3rd party analysis software
SureSelect Cancer CGP Assay ​ by Agilent Technologies news thumbnail
Editorial Article
Tools to advance precision oncology
21 Feb 2024